Company: RPTX
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001193125-25-283336
Chunk: 5

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 2
Chunk 5
---
 a “CVR”) for each common share, entitling them to receive certain contingent cash payments. In addition to shareholder approval, the Transaction is subject to the approval of the Superior Court of Quebec and other customary closing conditions. The Transaction is expected to close in the first quarter of 2026. The Arrangement Agreement includes a termination fee of US$2.0 million, payable by the Company under certain circumstances, including in connection with the Company’s entry into an agreement with respect to a Superior Proposal (as defined in the Arrangement Agreement).

Strategic Re-Prioritization

In January 2025, we announced a re-alignment of resources and a re-prioritization of our clinical portfolio to focus on the continued advancement of our Phase 1 clinical programs, RP-3467 and RP-1664. 

On February 24, 2025, we approved a phased reorganization to reduce our workforce by approximately 75% by the fourth quarter of 2025, with our remaining employees primarily focused on the continued advancement of our Phase 1 clinical programs, RP-3467 and RP-1664. 

In May 2025, we announced the out-licensing of our discovery platforms to DCx Biotherapeutics Corporation, or DCx, and in July 2025, we announced an exclusive out-licensing agreement with Debiopharm International S.A., or Debiopharm, for lunresertib. 

In light of the Arrangement Agreement announced in November 2025, we expect to maintain a minimal workforce to finalize the Transaction. 

Recent Developments 

•Worldwide license agreement with Debiopharm for lunresertib

oIn July 2025, we entered into an exclusive worldwide license agreement with Debiopharm for lunresertib, a first-in-class oncology PKMYT1 inhibitor. Under the terms of the agreement, we received a $10 million upfront payment, a $1.6 million payment for the transfer of clinical trial materials, and are eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, and single-digit royalties on global net sales. This agreement builds on the success of the clinical study and collaboration agreement we entered into with Debipharm to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective